Novel ldl-receptor
CA 2286313 C · Owner: Hess, John Wilfred · Inventors: Nakagawa, Yusuke; Todd, John Andrew; Metzker, Michael Lee
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel receptor, "LDL-receptor related protein-3" ("LRP-3") is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences oligonucleotide primers and probes, polypeptides pharmaceutical compositions, methods of diagnosis or prognosis and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases such as glomerulonephritis, diseases and disorders …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 1998 and granted January 11, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 15, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.